MET signaling: Novel targeted inhibition and its clinical development in lung cancer

Yan Feng, Praveena S. Thiagarajan, Patrick C. Ma

Research output: Contribution to journalReview article

75 Citations (Scopus)

Abstract

MET is a versatile receptor tyrosine kinase within the human kinome which is activated by its specific natural ligand hepatocyte growth factor (HGF). MET signaling plays an important physiologic role in embryogenesis and early development, whereas its deregulation from an otherwise quiescent signaling state in mature adult tissues can lead to upregulated cell proliferation, survival, scattering, motility and migration, angiogenesis, invasion, and metastasis in tumorigenesis and tumor progression. Studies have shown that MET pathway is activated in many solid and hematological malignancies, including lung cancer, and can be altered through ligand or receptor overexpression, genomic amplification, MET mutations, and alternative splicing. The MET signaling pathway is known to be an important novel target for therapeutic intervention in human cancer. A number of novel therapeutic agents that target the MET/HGF pathway have been tested in early-phase clinical studies with promising results. Phase 3 studies of MET targeting agents have just been initiated. We will review the MET signaling pathway and biology in lung cancer and the recent clinical development and advances of MET/HGF targeting agents with emphasis on discussion of issues and strategies needed to optimize the personalized therapy and further clinical development.

Original languageEnglish (US)
Pages (from-to)459-467
Number of pages9
JournalJournal of Thoracic Oncology
Volume7
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Hepatocyte Growth Factor
Lung Neoplasms
Ligands
Alternative Splicing
Receptor Protein-Tyrosine Kinases
Hematologic Neoplasms
Embryonic Development
Neoplasms
Cell Survival
Carcinogenesis
Therapeutics
Cell Proliferation
Neoplasm Metastasis
Mutation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

@article{6570d6a998674c9cb5ad947d56056816,
title = "MET signaling: Novel targeted inhibition and its clinical development in lung cancer",
abstract = "MET is a versatile receptor tyrosine kinase within the human kinome which is activated by its specific natural ligand hepatocyte growth factor (HGF). MET signaling plays an important physiologic role in embryogenesis and early development, whereas its deregulation from an otherwise quiescent signaling state in mature adult tissues can lead to upregulated cell proliferation, survival, scattering, motility and migration, angiogenesis, invasion, and metastasis in tumorigenesis and tumor progression. Studies have shown that MET pathway is activated in many solid and hematological malignancies, including lung cancer, and can be altered through ligand or receptor overexpression, genomic amplification, MET mutations, and alternative splicing. The MET signaling pathway is known to be an important novel target for therapeutic intervention in human cancer. A number of novel therapeutic agents that target the MET/HGF pathway have been tested in early-phase clinical studies with promising results. Phase 3 studies of MET targeting agents have just been initiated. We will review the MET signaling pathway and biology in lung cancer and the recent clinical development and advances of MET/HGF targeting agents with emphasis on discussion of issues and strategies needed to optimize the personalized therapy and further clinical development.",
author = "Yan Feng and Thiagarajan, {Praveena S.} and Ma, {Patrick C.}",
year = "2012",
month = "2",
doi = "10.1097/JTO.0b013e3182417e44",
language = "English (US)",
volume = "7",
pages = "459--467",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "2",

}

MET signaling : Novel targeted inhibition and its clinical development in lung cancer. / Feng, Yan; Thiagarajan, Praveena S.; Ma, Patrick C.

In: Journal of Thoracic Oncology, Vol. 7, No. 2, 02.2012, p. 459-467.

Research output: Contribution to journalReview article

TY - JOUR

T1 - MET signaling

T2 - Novel targeted inhibition and its clinical development in lung cancer

AU - Feng, Yan

AU - Thiagarajan, Praveena S.

AU - Ma, Patrick C.

PY - 2012/2

Y1 - 2012/2

N2 - MET is a versatile receptor tyrosine kinase within the human kinome which is activated by its specific natural ligand hepatocyte growth factor (HGF). MET signaling plays an important physiologic role in embryogenesis and early development, whereas its deregulation from an otherwise quiescent signaling state in mature adult tissues can lead to upregulated cell proliferation, survival, scattering, motility and migration, angiogenesis, invasion, and metastasis in tumorigenesis and tumor progression. Studies have shown that MET pathway is activated in many solid and hematological malignancies, including lung cancer, and can be altered through ligand or receptor overexpression, genomic amplification, MET mutations, and alternative splicing. The MET signaling pathway is known to be an important novel target for therapeutic intervention in human cancer. A number of novel therapeutic agents that target the MET/HGF pathway have been tested in early-phase clinical studies with promising results. Phase 3 studies of MET targeting agents have just been initiated. We will review the MET signaling pathway and biology in lung cancer and the recent clinical development and advances of MET/HGF targeting agents with emphasis on discussion of issues and strategies needed to optimize the personalized therapy and further clinical development.

AB - MET is a versatile receptor tyrosine kinase within the human kinome which is activated by its specific natural ligand hepatocyte growth factor (HGF). MET signaling plays an important physiologic role in embryogenesis and early development, whereas its deregulation from an otherwise quiescent signaling state in mature adult tissues can lead to upregulated cell proliferation, survival, scattering, motility and migration, angiogenesis, invasion, and metastasis in tumorigenesis and tumor progression. Studies have shown that MET pathway is activated in many solid and hematological malignancies, including lung cancer, and can be altered through ligand or receptor overexpression, genomic amplification, MET mutations, and alternative splicing. The MET signaling pathway is known to be an important novel target for therapeutic intervention in human cancer. A number of novel therapeutic agents that target the MET/HGF pathway have been tested in early-phase clinical studies with promising results. Phase 3 studies of MET targeting agents have just been initiated. We will review the MET signaling pathway and biology in lung cancer and the recent clinical development and advances of MET/HGF targeting agents with emphasis on discussion of issues and strategies needed to optimize the personalized therapy and further clinical development.

UR - http://www.scopus.com/inward/record.url?scp=84858341589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858341589&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3182417e44

DO - 10.1097/JTO.0b013e3182417e44

M3 - Review article

C2 - 22237263

AN - SCOPUS:84858341589

VL - 7

SP - 459

EP - 467

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 2

ER -